NCT05677152View on ClinicalTrials.gov

Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2030

Conditions

OrthopedicsTraumatology

Interventions

DRUG

Intravenous Infusion of Aclasta®

Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)

Trial Locations (1)

1120

RECRUITING

Jakob Schanda, Vienna

All Listed Sponsors

collaborator

Ludwig Boltzmann Institute for Traumatology - The research center in cooperation with AUVA

OTHER_GOV

collaborator

CCSRM Clinical Center for Studies in Regenerative Medicine in cooperation with the Ludwig Boltzmann Institute for Traumatology

UNKNOWN

lead

AUVA Traumazentrum Vienna Site UKH Meidling

OTHER

NCT05677152 - Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder | Biotech Hunter | Biotech Hunter